Neurocrine Biosciences Inc vs Seagate Technology Holdings PLC — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Seagate Technology Holdings PLC trades at $782.65 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 12.3× Neurocrine Biosciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Seagate Technology Holdings PLC for 41 Days on average.
| NBIX | STX | |
|---|---|---|
Market Cap | $14.36B | $176.19B |
Volume | 1,237,180 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $185.50 | $1.09K |
52-Week Low | $123.10 | $211.63 |
Typical Hold Time | 23 Days | 41 Days |
Enterprise Value | $14.37B | $178.34B |
Dividend Yield | — | 0.38% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Seagate Technology (STX) trades at $780.39, down 3.34% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamental performance with Q2 2026 EPS beating expectations at $5.71 versus $5.10, and maintains robust profitability with 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price below key pivot points, though RSI suggests potential oversold conditions at 24.89.
Despite near-term competitive pressures, Seagate's dominant position in AI storage and strong earnings trajectory support long-term growth. The consensus price target of $1,130 represents 45% upside potential, but investors face risks from pricing pressure and market share erosion as Toshiba expands capacity in 2027.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →